These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 17646551)

  • 1. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
    Cubanski J; Neuman P
    Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.
    Thomas CP; Sussman J; ;
    Issue Brief (Mass Health Policy Forum); 2007 May; (32):1-32. PubMed ID: 17546802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation.
    Evans-Molina C; Regan S; Henault LE; Hylek EM; Schwartz GR
    J Am Geriatr Soc; 2007 Jul; 55(7):1038-43. PubMed ID: 17608876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Part D: selected issues for pharmacists and beneficiaries in 2007.
    Kilian J; Stubbings J
    J Manag Care Pharm; 2007; 13(1):59-65. PubMed ID: 17269838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Part D-a roundtable discussion of current issues and trends.
    Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
    J Manag Care Pharm; 2009; 15(1 Suppl A):3-9. PubMed ID: 19125555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2008.
    Depue R; Stubbings J
    J Manag Care Pharm; 2008; 14(1):50-60. PubMed ID: 18240882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
    Buttorff C; Andersen MS; Riggs KR; Alexander GC
    Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
    Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
    Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug plan design incentives among Medicare prescription drug plans.
    Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
    Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unintended effects of the Medicare Part D low income subsidy.
    Decarolis F
    Health Policy; 2015 May; 119(5):597-603. PubMed ID: 25716285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first look at the new Medicare prescription drug plans.
    Frakt AB; Pizer SD
    Health Aff (Millwood); 2006; 25(4):W252-61. PubMed ID: 16720588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.